Latest Deals

Edwards has exercised its option to acquire Endotronix, enhancing its capabilities in the heart failure management space. Credit: Umaporn Kensila / Shutterstock

Edwards Lifesciences has announced strategic acquisitions or JenaValve Technology and Endotronix totalling nearly $1.2bn. JenaValve provides transcatheter treatment of aortic regurgitation (AR). The company’s Trilogy Heart Valve System is expected to receive approval from the US Food and Drug Administration in late 2025 to treat AR. Edwards has also exercised its option to acquire Endotronix.

Roche has completed the previously announced acquisition of LumiraDx‘s Point of Care technology for up to $350m. The acquisition, which was finalised following the receipt of all necessary antitrust and regulatory clearances, marks a significant expansion of Roche’s diagnostics portfolio. Roche said the acquisition is set to enhance its capabilities in delivering decentralised patient care and improve access to critical health information. 

Hologic has closed the acquisition of UK-based breast cancer surgery technologies developer Endomagnetics (Endomag) for approximately $310m. The deal between the parties was signed in April 2024. Endomag is engaged in developing technologies for breast surgery, including the Magseed marker, Magtrace lymphatic tracing injectable, and the Sentimag platform. 

Magenta Medical has raised $105m to support clinical trials in the US evaluating the technology. Israel-headquartered Magenta has already tested its Elevate technology in a first-in-human study and early feasibility study in patients undergoing high-risk percutaneous coronary interventions. Positive safety and efficacy results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, US, in October 2023.